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OBJECTIVES We studied the effects of dehydroepiandrosterone (DHEA), an abundant adrenal androgen,
on two key early events of atherogenesis: 1) human monocyte adhesion to vascular
endothelium, and 2) human foam cell formation.
BACKGROUND In the U.S., where DHEA is available without prescription, there has recently been a rapid
increase in unsupervised self-administration of DHEA. The vascular biologic effects of
DHEA are largely unknown, however.
METHODS Regarding adhesion, human umbilical vein endothelial cells (HUVECs), exposed to either
DHEA (42 or 420 nmol/l) or control, were incubated with human monocytes, and adhesion
was measured by hemocytometry. Surface expression of endothelial cell adhesion molecules
was measured by ELISA. Regarding foam cell formation, studies of lipid loading were
performed on macrophages treated with DHEA or control and/or the androgen receptor
antagonist hydroxyflutamide (HF) (4 mol/l). Intracellular cholesterol and cholesteryl esters
(CE) were quantified by high-performance liquid chromatography. Expression of foam cell
formation-related genes was measured by reverse-transcription polymerase chain reaction.
RESULTS DHEA produced a dose-dependent receptor-mediated increase in the male macrophage CE
content (up to 120  4% of control values, p  0.015). DHEA upregulated messenger
ribonucleic acid expression of the lipoprotein-processing enzymes acyl coenzyme A:choles-
terol acyltransferase I and lysosomal acid lipase by 3.4- and 5.3-fold, respectively (p  0.05
vs. control), but had no effect on scavenger receptor expression (p  0.2). There was no
significant effect of DHEA on monocyte–endothelial adhesion (10% change in values, p 
0.56) or endothelial cell expression of cell adhesion molecules (p  0.1).
CONCLUSIONS DHEA increases human macrophage foam cell formation, a potentially pro-atherogenic
effect. This effect appears to be mediated via the androgen receptor and involves the
upregulation of lipoprotein-processing enzymes. (J Am Coll Cardiol 2003;42:1967–74)
© 2003 by the American College of Cardiology Foundation
Dehydroepiandrosterone (DHEA) and its sulfate ester
(DHEAS) are sex hormone precursors of mainly adrenal
origin, with weak androgenic action. To date, DHEA and
DHEAS have been an endocrine paradox: they are the most
abundant steroids in the circulation, yet their biologic
significance is unknown. For over four decades, it has been
hypothesized that DHEA may play a role in preventing the
development of atherosclerosis and coronary artery disease
(1). In recent years, there has been a surge of public interest
in DHEA because of its reported anti-atherosclerotic and
anti-aging effects. In the U.S., where DHEA is available
without prescription, there has been a rapid increase in
unsupervised self-administration, despite the fact that none
of its purported benefits have been proven in the context of
a large, randomized, placebo-controlled clinical trial (2).
The most persuasive evidence for an anti-atherogenic
effect comes from a prospective cohort study of 242 men in
whom a low baseline level of DHEAS (140 g/dl) was
associated with a threefold increase in cardiovascular mor-
tality over a follow-up period of 12 years (3). However,
subsequent prospective epidemiologic studies in women (4)
and in other male cohorts (5–9) have failed to yield
consistent results with respect to the relationship between
DHEAS levels and cardiovascular outcomes. In animal
experiments, DHEA administration has been reported to
reduce aortic atherosclerosis in cholesterol-fed rabbits with
or without aortic intimal injury (10,11). These anti-
atherogenic effects were observed without significant
changes in plasma lipids, suggesting a direct effect of
DHEA on the arterial wall. It is difficult, however, to
extrapolate these animal findings to humans, particularly as
adrenal production of DHEA or DHEAS in most experi-
mental animals is nonexistent or minute, and the experi-
mental work is based on pharmacologic doses of exogenous
hormones. To date, few mechanistic studies have examined
the vascular effects of DHEA on humans.
There is increasing evidence that sex steroids play a role
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in the regulation of atherogenic processes. A prominent
early event in atherogenesis is the adherence of monocytes
to endothelial cells and their subsequent transmigration into
the subendothelial space to differentiate into macrophages
(12). The macrophages then accumulate very large amounts
of cholesteryl ester (CE), giving them a foamy appearance
(hence, “foam” cell) (13). In a series of human in vitro
studies, we recently reported that androgens increase mono-
cyte adhesion to endothelial cells and endothelial cell
expression of vascular cell adhesion molecule-1 (VCAM-1,
a mediator of monocyte–endothelial adhesion) (14). We
also demonstrated that androgens, estrogen, and progester-
one all exert gender-specific effects on human macrophage
foam cell formation (15–17). As DHEA is both a weak
androgen and a universal precursor for a number of andro-
genic and estrogenic products, we therefore sought to
evaluate the effects of DHEA on two key early events of
atherogenesis: human monocyte adhesion to vascular endo-
thelium and foam cell formation.
METHODS
Human monocyte adhesion to vascular endothelial cells
and endothelial cell adhesion molecule expression. EN-
DOTHELIAL CELL HARVESTING AND CULTURE. Human
umbilical vein endothelial cells (HUVECs) were harvested
enzymatically from male infant umbilical cords under sterile
conditions, as previously described by us (14). Human
coronary artery endothelial cells (HCAECs) were purchased
from Cell Applications, Inc. (San Diego, California). En-
dothelial cells (passages 2 to 4 for HUVECs and passages 5
to 10 for HCAECs) were grown to confluence before sex
steroid hormone treatment and were used within 72 h. The
purity of the endothelial cell monolayers was confirmed
macroscopically by their cobblestone pattern and periodi-
cally by cell staining with a monoclonal antibody specific for
von Willebrand factor. At the end of the 48-h treatments,
cell viability was 95% (by trypan blue exclusion) for each
condition.
ISOLATION OF HUMAN MONOCYTES. White cell concen-
trates (Red Cross Blood Bank) were obtained from the
peripheral blood of healthy individual men. Monocytes were
isolated by counterflow centrifugation elutriation, as previ-
ously described (15). Monocyte purity was 90% and
viability was 95% by Trypan blue exclusion in all experi-
ments. Monocytes were either: 1) resuspended in RPMI
containing 2% human serum and used immediately for
adhesion studies; or 2) resuspended in phenol red-free
RPMI (Life Technologies, Carlsbad, California) for studies
of lipid loading.
MONOCYTE– ENDOTHELIAL CELL ADHESION ASSAY. Con-
fluent HUVEC monolayers were established in 24-mm-
diameter wells before incubation for 48 h with the following
treatments: 1) vehicle control (0.1% ethanol); 2) DHEA at
a physiologic concentration (42 nmol/l); and 3) DHEA at a
supraphysiologic concentration (420 nmol/l). Each treat-
ment group was divided after 24 h of hormone treatment
into basal and stimulated states, with the latter receiving
interleukin-1-beta (IL-1-beta; Genzyme Corp., Cam-
bridge, Massachusetts) at 50 U/ml for the final 24-h period.
Each experiment used at least triplicate wells for each
condition. Separate adhesion experiments were performed
three times for all treatment groups. As described previously
(15), the adhesion assay involved cell counting before and
after a 1-h period of monocyte addition to the endothelial
monolayer (Neubauer hemocytometer, Weber Scientific,
London, UK). The initial suspensions and the suspension
from each well were counted four times by an observer
blinded to the treatment conditions. This method has been
shown to have a low intra-observer error, with a coefficient
of variation of 5%, and maximal basal adhesion after 1 h
of incubation (14).
ENDOTHELIAL CELL ADHESION MOLECULE EXPRES-
SION. The cell-surface expression of adhesion molecules on
the endothelial cell monolayers exposed to different treat-
ments was assessed with an ELISA technique (15) using
HUVECs and HCAECs. Confluent cell monolayers were
established in 96-well plates and exposed for 48 h to the
control or hormone treatments as outlined earlier, with or
without IL-1-beta stimulation (50 U/ml) for the last 24 h of
treatment. Monoclonal antibodies (obtained from Becton-
Dickinson [Franklin Lakes, New Jersey], unless where
indicated) to intercellular adhesion molecule-1 (ICAM-1),
VCAM-1, E-selectin, or isotype mouse immunoglobulin G
(ICN Immunobiologicals, Costa Mesa, California) (0.1 mg
in 100 ml of Hank’s Balanced Salt Solution with 10%
heat-inactivated human serum) were added for 30 min
before a 30-min incubation with sheep anti-mouse anti-
body/horseradish peroxidase conjugate (Amersham Interna-
tional) (1:500 in 100 ml of Hank’s Balanced Salt Solution
with 10% heat-inactivated human serum and 0.05% Tween-
20). The ABTS substrate (Kirkegaard and Perry Laborato-
ries, Gaithersburg, Maryland) was then added, and the
results were expressed as units of optical density, measured
Abbreviations and Acronyms
ACAT  acyl coenzyme A:cholesterol acyltransferase I
CE  cholesteryl ester
DHEA  dehydroepiandrosterone
DHEAS  dehydroepiandrosterone sulfate
HCAEC  human coronary artery endothelial cell
HF  hydroxyflutamide
HUVEC  human umbilical vein endothelial cell
ICAM-1  intercellular adhesion molecule-1
IL-1-beta  interleukin-1-beta
LAL  lysosomal acid lipase
LDL  low-density lipoprotein
MDM  monocyte-derived macrophage
PBS  phosphate-buffered saline
RT-PCR  reverse-transcription polymerase chain
reaction
VCAM-1  vascular cell adhesion molecule-1
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at 414 nm with an ELISA plate reader (Titretek Multiscan,
Flow Laboratories, Rickmansworth, UK).
Human monocyte-derived macrophage (MDM) foam-
cell formation. CULTURE AND LIPID LOADING OF HUMAN
MDMS. Monocytes isolated by elutriation were cultured
in phenol red-free RPMI containing 10% postmenopausal
human serum. From days 3 to 12, the following treatments
were added with each media change: 1) vehicle control
(0.1% ethanol); 2) DHEA at a variety of physiologic (4.2,
8.4, and 42 nmol/l) or supraphysiologic (420 nmol/l) con-
centrations; 3) DHEA at 42 nmol/l and hydroxyflutamide
(HF), a nonsteroidal androgen-receptor antagonist at
4 mol/l; and 4) HF only at 4 mol/l. Each experiment
used at least triplicate cultures for each condition.
After macrophage differentiation, lipid loading was
achieved on days 9 through 12 during a 72-h incubation
with lipid loading medium (50 mg/ml acetylated low-
density lipoprotein [LDL] in phenol red-free RPMI con-
taining 10% [vol./vol.] lipoprotein-deficient human serum
[density 1.25 g/ml]). Cell viability for each treatment
condition was established by trypan blue exclusion, with
viability levels of 90% to 94%.
PREPARATION AND ACETYLATION OF LDL. Low density
lipoprotein (1.05  density  1.02 g/ml) was isolated from
the plasma of healthy, normolipidemic fasting subjects by
two-step centrifugation at 10°C with a Beckman L8-M
centrifuge and Ti70 rotor at 50,000 rpm (242,000 g) for
24 h. The LDL was dialyzed four times against 1 l of
deoxygenated phosphate-buffered saline (PBS) (calcium and
magnesium free; Flow Laboratories) containing 0.1 mg/ml
chloramphenicol (Boehringer Mannheim, Mannheim, Ger-
many) and 1.0 mg/ml EDTA. Soon after isolation, the
LDL was acetylated at 4°C by a modification of a previous
method (18) with 6 ml acetic anhydride per 1 mg LDL
protein.
PREPARATION OF MACROPHAGE CELL EXTRACTS. After
the human MDMs were washed three times with ice-cold
PBS, cells were lysed with 0.6 ml of cold 0.2 mol/l NaOH
at 4°C for 15 min. From the lysate, 0.2 ml was used for
cell protein estimation, and the remaining 0.4 ml was added
to 0.6 ml ice-cold PBS and immediately extracted into
methanol (2.5 ml) and hexane (5 ml) in the presence of
20 mmol/l butylated hydroxytoluene (Sigma, St. Louis,
Missouri) and 2 mmol/l EDTA. Samples were stored after
extraction at 80°C until analysis for free cholesterol and
CE was performed, usually within seven days.
ENDOTHELIAL CELL AND MACROPHAGE LDL OXIDATION
STUDIES. Supernatant from control and DHEA-treated
(42 nmol/l) endothelial cells and macrophages were col-
lected after 24-h incubation with a lipid loading medium
containing 50 mg/ml LDL for quantification of oxidation
products. From the supernatant, 1 ml was added to 0.6 ml
ice-cold PBS and then extracted into methanol and hexane,
using the same protocol as for cell extracts.
ANALYSIS OF CHOLESTEROL, CES, AND CE OXIDATION
PRODUCTS. Cholesterol, CEs, cholesterol linoleate hy-
droperoxide, and alpha-tocopherol were separated and
quantified by reverse-phase high-performance liquid chro-
matography at room temperature on a C-18 column
(Supelco, Bellefonte, Pennsylvania), as described previously
(19). Cholesterol, CEs, and alpha-tocopherol were quanti-
fied by the derivation of standard curves by use of commer-
cially available standards (Sigma). The curves expressed a
linear relationship between the chromatographic peak areas
and the mass of the standard, which enabled us to quantify
individual cholesterol compounds in nanomoles per milli-
gram of cell protein.
PROTEIN ESTIMATION. All protein estimations were per-
formed by the bicinchoninic acid method (Sigma) with
bovine serum albumin used as a standard using 0.2 ml cell
lysate. Samples were incubated for 60 min at 60°C before
measurement of absorbance at 562 nm.
RELATIVE REAL-TIME REVERSE-TRANSCRIPTION POLYMER-
ASE CHAIN REACTION (RT-PCR). The effect of DHEA on
the macrophage expression of foam cell formation–related
genes was undertaken by relative real-time RT-PCR with
SYBR Green I monitoring. The genes assayed included acyl
coenzyme A:cholesterol acyltransferase I (ACAT), lysoso-
mal acid lipase (LAL), and scavenger receptors A1 and A2.
Ribonucleic acid was isolated from control and DHEA-
treated (42 nmol/l) macrophages at maturation (day 9).
Reverse transcription of each RNA sample was performed
in duplicate, according to standard protocols. Relative real-
time PCR reactions were performed in duplicate for each
cDNA sample for each gene of interest (Applied Biosys-
tems, Inc. [ABI], model 7700 Sequence Detector, PE
Biosystems) and analyzed using ABI Prism Sequence De-
tector software version 1.6.3 (PE Biosystems, Foster City,
California). The housekeeping gene, 60S rRNA, was also
measured for normalization of real-time PCR results.
The primer sequences were: ACAT forward 5-
AGTTGACAGCAGAGGCAGAG-3 and reverse 5-
GGATAAAGAGAATGAGGAGGG-3; LAL forward
5-GCAACAGCAGAGGAAATAC-3 and reverse 5-
GAGAATGACCCACATAATACAC-3; scavenger re-
ceptor A1 forward 5-CACAATCAACAGGAGGAC-3
and reverse 5-CAATGAGAGGGATGAGAAC; and
scavenger receptor A2 forward 5-TACTCCACCA-
TCACCTCTCTCC-3 and reverse 5-TCGCTTT-
GCTTGACTGAAC-3.
Statistical analysis. Adhesion assay, ELISA, lipid loading,
and gene expression data are expressed as the mean value 
SEM of at least triplicate wells, per experiment per condi-
tion per donor. Results for the adhesion assays and ELISAs
for cell adhesion molecule expression are expressed as a
percentage of the control condition within each experiment,
as each experiment involved endothelial cells and/or mono-
cytes from different donors. In the case of lipid loading
experiments, the results for each condition in each donor
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were calculated as a percentage of control values. Groups of
three or more conditions were compared by one-way anal-
ysis of variance (ANOVA), followed by the Student-
Newman-Keuls test for multiple pairwise comparisons (for
significant ANOVA results). Statistical comparisons be-
tween two treatment conditions were performed using an
independent samples t test, with adjustment for multiple
comparisons, where appropriate, in accordance with Hoch-
berg’s modification of the Bonferroni procedure. Statistical
significance was inferred at a two-sided p value of 0.05.
SPSS software (version 9.0) was used for statistical analyses.
RESULTS
Monocyte– endothelial cell adhesion and expression of
endothelial cell adhesion molecules. Exposure to
DHEA, at physiologic (42 nmol/l) and supraphysiologic
(420 nmol/l) concentrations, had no significant effect on
monocyte adhesion to endothelial cell monolayers in the
basal state (108  3% and 108  8% for DHEA at 42 and
420 nmol/l, respectively, vs. control; p  0.56) (Fig. 1).
Treatment of endothelial cell monolayers with IL-1-beta
significantly increased monocyte–endothelial adhesion by
66  10% (p  0.02), as expected from previous work.
However, DHEA, even at supraphysiologic concentrations,
had no effect on monocyte–endothelial adhesion in the
IL-1-beta–activated state (102  4% and 105  3% for
DHEA at 12 and 120 ng/ml, respectively, vs. vehicle
control; p  0.56 by ANOVA) (Fig. 1). The effect of
DHEA treatment on endothelial cell-surface adhesion mol-
ecule expression in both basal and IL-1-beta–stimulated
states was also examined using an ELISA technique. Co-
incubation of endothelial cells with IL-1-beta for 24 h
increased cell-surface expression of all three molecules:
ICAM-1, VCAM-1, and E-selectin. Administration of
DHEA, at both physiologic and supraphysiologic concen-
trations, however, had no significant effect on expression of
VCAM-1, ICAM-1, or E-selectin in the basal or IL-1-
beta–stimulated states in HUVECs or HCAECs (p  0.1
by ANOVA for all cell adhesion molecules) (Fig. 2).
Effects of DHEA on macrophage CE accumulation. The
effect of DHEA on MDM foam cell formation was studied
over a range of physiologic (4.2 to 42 nmol/l) and supra-
physiologic (420 nmol/l) concentrations. Exposure to
DHEA produced a dose-dependent increase in the male
macrophage CE content, which was maximal at a physio-
logic concentration of 42 nmol/l (104  5%, 105  5%,
120  4%, and 117  8% for DHEA at 4.2, 8.4, 42, and
420 nmol/l, respectively, as a percentage of control values;
p  0.015 by ANOVA) (Fig. 3). The DHEA-mediated
effect on intracellular CE accumulation was abrogated by
co-administration of the nonsteroidal androgen receptor
antagonist HF (CE as a percentage of control value, 91 
5% for DHEA at 42 nmol/l with HF, p  0.1 vs. control).
Hydroxyflutamide alone did not significantly alter the CE
content (101  6%, p  0.8 vs. control). Free cholesterol
content was not significantly altered by DHEA exposure
(free cholesterol as a percentage of control values:
102  4%, 104  1%, 112  8%, and 90  8% for DHEA
at 4.2, 8.4, 42, and 420 nmol/l, respectively; p  0.3 by
ANOVA).
Mechanistic studies of the effect of DHEA on foam cell
formation. EFFECT OF DHEA ON LDL OXIDATION BY ENDO-
THELIAL CELLS AND MACROPHAGES. To study the effect of
DHEA on LDL oxidation, samples of media at the end of
the loading period were extracted and analyzed for native
and oxidized lipids and alpha-tocopherol content. No dif-
ferences were found in any of the oxidation parameters
(including alpha-tocopherol, cholesteryl linoleate, and cho-
lesteryl linoleate hydroperoxide levels) measured between
DHEA-treated and control cultures in both HCAECs and
MDMs (p  0.1; data not shown). Consistent with previ-
ous studies on cell-mediated oxidation (19), only a very
small proportion of cholesteryl linoleate, the major oxidiz-
able lipid in LDL, was converted to cholesteryl linoleate
hydroperoxide during the incubation (2.89  0.22% for
DHEA at 42 nmol/l and 2.69  0.42% for control in
HCAECs; 3.15  0.15% for DHEA at 42 nmol/l and
3.1  0.2% for control in MDMs; cholesteryl linoleate
hydroperoxide as a percentage of cholesteryl linoleate; p 
0.7 vs. control).
EFFECTS OF DHEA ON GENE EXPRESSION. By relative
RT-PCR, we examined the effect of physiologic concentra-
tions of DHEA (42 nmol/l) on the expression of foam cell
formation–related genes, including ACAT, LAL, and mac-
rophage scavenger receptors A1 and A2. DHEA upregu-
lated the expression of ACAT by 3.4-fold and LAL by
5.3-fold (p  0.05 vs. control for both genes) (Fig. 4A). By
comparison, DHEA exposure had no effect on the expres-
sion of scavenger receptors A1 or A2 (p 0.2 vs. control for
both genes) (Fig. 4B).
DISCUSSION
The effect of DHEA and its sulfated prohormone,
DHEAS, on human atherogenic processes has received very
little attention, despite longstanding conjecture that adrenal
Figure 1. Monocyte adhesion to endothelium (in the basal or interleukin-
1-beta [IL-1-beta]–stimulated state) for each treatment condition, ex-
pressed as a percentage of control values. Dehydroepiandrosterone
(DHEA) (in young adults and at supraphysiologic concentrations) had no
significant effect on monocyte adhesion to endothelium (p  0.56 by
analysis of variance [ANOVA] for adhesion in either the basal or
IL-1-beta–stimulated state).
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androgens may be atheroprotective. Key early events in
atherogenesis include monocyte adhesion to endothelium
and macrophage lipid loading. In the present study, we
found that physiologic concentrations of DHEA increased
CE formation in male donor human MDMs, an effect
antagonized by androgen receptor blockade. By RT-PCR, we
Figure 2. Endothelial cell-surface expression of vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and E-selectin
for each treatment group in the basal (A) and IL-1-beta–stimulated (B) states. Results are expressed as a percentage of control values. DHEA had no
significant effect on endothelial cell-surface expression of VCAM-1, ICAM-1, or E-selectin (p  0.1 by ANOVA for each cell adhesion molecule [CAM]
in each treatment group). Abbreviations as in Figure 1.
Figure 3. Exposure to DHEA was associated with a dose-dependent increase in cholesteryl ester (CE) accumulation in human macrophages from male donors,
over the physiologic range (4.2 to 42 nmol/l). This effect is abrogated by co-incubation with the androgen receptor antagonist HF. *p 0.015 by ANOVA. There
was a polynomial relationship between the DHEA concentration and macrophage CE content (r  0.997). Abbreviations as in Figure 1.
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have also shown that DHEA exposure increases the expression
of two important lipoprotein-processing enzymes implicated in
foam cell formation: LAL and ACAT. In other mechanistic
studies, DHEA was found to have no significant effect on
LDL oxidation or on scavenger receptor expression. In con-
trast to foam cell formation, DHEA had no direct effect on
either human monocyte adhesion to endothelial cells or endo-
thelial cell expression of the major cell adhesion molecules
E-selectin, ICAM-1, and VCAM-1.
Although initially surprising, the finding of a potentially
pro-atherogenic effect of DHEA on male human macro-
phage foam cell formation is consistent with our recent
demonstration that androgen exposure (using the non-
aromatizable physiologic androgen dihydrotestosterone) is
associated with increased CE accumulation in male but not
female MDMs (16). The effect of DHEA on MDM CE
accumulation was maximal at a concentration consistent
with that found in a young male adults (42 nmol/l). Like the
effect observed with dihydrotestosterone (16), the effect of
DHEA on foam cell formation could be abrogated by HF,
suggesting a common androgen receptor-dependent effect.
In mechanistic experiments evaluating the role of DHEA
in foam cell formation, we examined the effects of DHEA
on: 1) the oxidation of LDL; and 2) the expression of key
foam cell formation–related genes. Oxidation of LDL,
postulated to be an important event in atherogenesis, has
been shown to accelerate macrophage CE accumulation
(19). We found that DHEA had no effect on LDL
oxidation by endothelial cells or macrophages, as measured
by a number of parameters, including the accumulation of
CE hydroperoxides. In contrast, we found that physiologic
concentrations of DHEA upregulated macrophage genes
involved in lysosomal lipoprotein processing (i.e., LAL) and
intracytoplasmic cholesterol esterification (i.e., ACAT).
Lysosomal acid lipase plays a major role in the delivery of
atherogenic lipoproteins to the cell by hydrolyzing the CE
moiety from lipoproteins delivered to the lysosome via
endocytosis or phagocytosis into free cholesterol (20). This
newly hydrolyzed free cholesterol is then made available to
ACAT for intracytoplasmic synthesis of CEs. Increases in
both LAL and ACAT activities have thus been implicated
in promoting macrophage foam cell formation (13). In
contrast, DHEA had no effect on the expression of scaven-
ger receptors A1 or A2, receptors implicated in mediating
the influx of atherogenic lipoproteins into MDMs (21).
These gene expression findings are strongly consistent with
our recent demonstration that androgen (dihydrotestoster-
one) exposure in male donor MDMs is associated with
increased LAL and ACAT expression, but with no significant
effects on scavenger receptor expression (22). The congruence
between DHEA- and dihydrotestosterone-related effects on
MDM gene expression is consistent with the observed DHEA
effects being due to an androgenic mode of action.
In contrast to our current findings, Taniguchi et al. (23)
have reported that short-term exposure to DHEA inhibits
CE accumulation in the female-derived mouse macrophage
cell line J774A.1. However, it is difficult to extrapolate the
findings of this study to the human setting for a number of
Figure 4. Effects of dehydroepiandrosterone (DHEA) exposure on macrophage gene expression. (A) Gene expression examined by reverse-transcription
polymerase chain reaction shows that DHEA at physiologic concentrations upregulates the lipoprotein-processing genes acyl coenzyme A:cholesterol
acyltransferase I (ACAT) and lysosomal acid lipase (LAL). (B) In contrast, DHEA exposure had no significant effect on expression of the scavenger
receptors A1 and A2. *p 0.05 versus control values for ACAT and LAL (vs. p 0.2 for scavenger receptors A1 and 2). Open columns control; shaded
columns  DHEA at 42 nmol/l.
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reasons: 1) adrenal production of DHEA or DHEAS in
mice is minimal, making the relevance of these observations
to humans doubtful; and 2) a female-derived macrophage
cell line was used (which may not have expressed the
androgen receptor).
We have previously reported that dihydrotestosterone
exposure is also associated with increased human monocyte–
endothelial adhesion via enhanced endothelial cell expres-
sion of VCAM-1 (14). On the other hand, estrogens inhibit
monocyte–endothelial adhesion and inhibit endothelial cell
expression of E-selectin, ICAM-1, and VCAM-1 (24).
Previous in vitro experiments have reported that human
endothelial cells possess the capacity to convert DHEA to
other biologically more potent sex steroids, particularly
androgens such as testosterone and dihydrotestosterone
(25). In our experiments, DHEA, even at supraphysiologic
concentrations, had no significant effect on monocyte–
endothelial cell adhesion or endothelial cell-surface expres-
sion of cell adhesion molecules, either at baseline or at
IL-1-beta–stimulated states. This neutral finding suggests
that DHEA does not simply exert androgen-like effects on
endothelial cells, at least compared with the potent non-
aromatizable androgen dihydrotestosterone.
DHEA in atherogenesis: evaluation of the biologic plau-
sibility of an effect. To evaluate the biologic plausibility of
a DHEA-mediated effect on atherogenesis, it is necessary to
consider differences in DHEA levels that are observed with
increasing age and variations in DHEA levels across differ-
ent populations.
Multiple prospective studies of middle-aged and elderly
subjects have investigated the relationship between
DHEAS levels and atherosclerosis. The results of these
studies have not been consistent with different studies
reporting either neutral, positive, or inverse relationships
between DHEAS levels and a variety of cardiovascular end
points (1). Consideration of the steep age-related decline in
DHEAS secretion may explain the apparent discrepancy
between such studies. In both men and women, DHEAS
levels reach a peak between the second and third decades of
life (26). Thereafter, levels decrease markedly with age; by
70 years of age, DHEAS levels are down to only 20% of
their peak values (26). In the context of the pathogenesis of
atherosclerotic lesions, the timing of peak DHEAS concen-
trations coincide with the progression of arterial fatty streaks
to a more advanced lesion morphology—the fibrous plaque.
All published prospective studies investigating the relation-
ship between DHEAS and atherosclerosis have been per-
formed in late-middle-age or elderly groups, where DHEA
and DHEAS concentrations are only a fraction of those in
young adulthood, and at a stage where atherosclerosis is
already well established. Therefore, prospective studies in-
vestigating the link between DHEAS and atherosclerosis
have been undertaken in age groups where the question of a
potential relationship between the hormone and the disease
may be least biologically relevant. Consistent with this
hypothesis, the most striking effects of DHEA on foam cell
formation in our study were observed at a DHEA concen-
tration consistent with those used in young male adults
(42 nmol/l), whereas concentrations in keeping with elderly
subjects (4.2 to 8.4 nmol/l) yielded only very modest effects
on CE accumulation.
As DHEAS concentrations decline in older age, it is
possible that DHEA and DHEAS exert different effects at
different stages in life. In the prospective study with the
youngest cohort of patients thus far, Hautanen et al. (6),
using data from the Helsinki Heart Study (a trial involving
dyslipidemic men with a mean age of 48 years), found that
after adjustment for smoking and age, men with high
DHEAS levels had a twofold increased risk of myocardial
infarction, as compared with men with lower levels. In
contrast, three prospective studies (5,7,8) in much older
men have reported neutral relationships between a variety
of nonfatal cardiovascular end points in men, including
nonfatal myocardial infarction and carotid atherosclerosis.
The picture is somewhat different when considering
prospective data relating DHEAS levels and male cardiovas-
cular mortality. Barrett-Connor et al. (3), using data from
the Rancho Bernardo Study of men aged 50 to 79 years, and
LaCroix et al. (5), studying men with a mean age of 57
years, have both reported an inverse relationship between
low DHEAS levels and a future risk of coronary heart
disease death. In comparison, two recent, large, prospective
studies in older male populations by Trivedi et al. (9) (mean
age 70 years) and Tilvis et al. (27) (age 75 years) failed to
find a consistent relationship between DHEAS levels and
cardiovascular mortality in the elderly male population. In
an expanded and updated analysis of the Rancho Bernardo
Study (28), which included 1,029 men (mean age 60 years)
followed up for 19 years, DHEAS was reported to provide
a far more modest protection against cardiovascular death in
men than originally reported. In this re-analysis of the
Rancho Barnardo Study data, it is notable that under 70
years of age, mean DHEAS levels tended to be higher in all
five-year age groups of men dead from cardiovascular
disease or from any cause compared with those still alive
(28). When above 70 years, however, all-cause and cardio-
vascular mortality was associated with lower DHEAS levels.
In contrast to men, prospective data on DHEAS and
female cardiovascular risk are more consistent. In four
prospective studies conducted in middle-aged to elderly
female study populations, no relationship was found be-
tween DHEAS levels and a variety of cardiovascular end
points, including cardiovascular mortality and carotid ath-
erosclerosis, as detected by ultrasonography (4,8,9,27).
Comparative data between populations also do not sup-
port an atheroprotective role of adrenal androgens. LaCroix
et al. (5) and Khaw (1) have both noted that there is great
variability in DHEAS levels between different populations.
For example, Japanese men in Japan have the lowest
age-specific mean DHEAS levels, and California Caucasian
men have the highest, with Hawaiian Japanese men having
levels in between. At 60 to 64 years of age, California men
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have approximately threefold (4.1 mol/l) and Japanese
Hawaiian men twofold (2.7 mol/l) the mean DHEAS
levels of Japanese men in Japan (1.4 mol/l). Correspond-
ing rates of coronary heart disease in these populations
follow the same pattern. Although such ecologic data can be
criticized on account of potential confounding factors, they
provide no support for the notion that low DHEAS levels
increase coronary heart disease rates.
Study limitations. Our in vitro experiments evaluated the
effects of direct DHEA administration to human MDMs
and endothelial cells. It is well known that DHEA and
DHEAS both serve as sex hormone precursors that are
converted by 3-beta-hydroxysteroid dehydrogenase to an-
drostenedione and then into potent androgens and/or es-
trogens in the peripheral tissues such as skin, adipose tissue,
breast lung, liver, kidney, and brain. It is therefore possible
that in the in vivo context, the “net” vascular biologic effect
of DHEA may be different, being the summation of
both direct effects (observed in this study) and indirect
effects via androgenic and estrogenic metabolites. Further-
more, although using human serum and primary cells, these
in vitro experiments may not necessarily represent the same
conditions as in the arterial wall in vivo.
Conclusions. In physiologic concentrations, DHEA in-
creases CE accumulation in male donor human MDMs. This
effect is mediated, at least in part, via the androgen receptor
and involves the upregulation of the lipoprotein-processing
enzymes ACAT and LAL. In contrast, DHEA has no
significant effect on human monocyte adhesion to endothelium
or expression of the cell adhesion molecules ICAM-1,
VCAM-1, and E-selectin. The potentially pro-atherogenic
effect of DHEA on male macrophage foam cell formation is
consistent with available interpopulation and age-specific epi-
demiologic data on DHEA concentrations, in the context of
the natural history of atherosclerosis. Further basic and clinical
studies are required to further elucidate the potentially adverse
cardiovascular effects of DHEA.
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